Program Director
CSL Behring · Assistant Professor and Program Director · Arcturus Therapeutics
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
57
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
NIH RePORTER
Trial papers
0
PubMed author-name match
Trials
Studies that name Program Director as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:59 UTC. Open this list on ClinicalTrials.gov
- N/ANCT07001280 · A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)CSL Behring · recruiting · Hereditary Angioedemas · study director
- N/ANCT06918223 · Assessing Patient Satisfaction and Confidence After Use of Educational Video to Augment Surgical Consent for Thyroid SurgeryThomas Jefferson University · recruiting · Thyroid Cancer · principal investigator
- Ph1/Ph2NCT06602531 · Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in AdultsArcturus Therapeutics, Inc. · completed · Influenza, Human · study director
- Ph3NCT06399289 · Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated With FIX TherapyCSL Behring · completed · Hemophilia B · study director
- Ph3NCT06279871 · Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in AdultsArcturus Therapeutics, Inc. · completed · COVID-19 · study director
- Ph1NCT06125691 · Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in AdultsArcturus Therapeutics, Inc. · completed · Influenza, Human · study director
- Ph3NCT06087640 · A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of AgeSeqirus · completed · Influenza, Human · study director
- Ph1NCT06028347 · Safety, Reactogenicity, and Immunogenicity Study of a Self-Amplifying MRNA Influenza Vaccine in Healthy AdultsSeqirus · completed · Influenza, Human · study director
- Ph3NCT06015282 · The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and OlderSeqirus · completed · Influenza, Human · study director
- N/ANCT06008938 · An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia BCSL Behring · recruiting · Hemophilia B · study director
- Ph1NCT05712538 · Safety, Tolerability, and Pharmacokinetics of ARCT-032 in Healthy Adult Subjects and Adults With Cystic Fibrosis.Arcturus Therapeutics, Inc. · completed · Cystic Fibrosis · study director
- Ph2NCT05501561 · Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of AgeSeqirus · completed · Influenza, Human · study director
- Ph3NCT05044195 · A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of AgeSeqirus · completed · Influenza, Human · study director
- Ph1/Ph2NCT05037097 · A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy AdultsArcturus Therapeutics, Inc. · completed · COVID-19, SARS-CoV-2 Infection, Corona Virus Infection · study director
- Ph2NCT04576702 · Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older AdultsSeqirus · completed · Influenza, Human · study director
- Ph3NCT04074928 · Safety and Immunogenicity Study of QIVc in Healthy Pediatric SubjectsSeqirus · completed · Influenza, Human, Virus Diseases · study director
- Ph3NCT03932682 · Efficacy Study With QIVc in Pediatric SubjectsSeqirus · completed · Influenza, Human · study director
- Ph1NCT03375606 · Assessing the Safety and Tolerability of CSL730 in Healthy Caucasian and Japanese AdultsCSL Behring · terminated · Healthy · study director
- Ph3NCT03221842 · Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant RecipientsCSL Behring · terminated · Antibody-mediated Rejection · study director
- Ph3NCT03165617 · Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects ≥2 to <18 Years of AgeSeqirus · completed · Influenza, Human · study director
- Ph3NCT02839330 · A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of AgeSeqirus · completed · Avian Influenza · study director
- Ph3
- N/ANCT02427217 · An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen DeficiencyCSL Behring · completed · Congenital Fibrinogen Deficiency · study director
- Ph3NCT02316353 · A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary AngioedemaCSL Behring · completed · Hereditary Angioedema Types I and II · study director
- Ph3NCT02281201 · Study of a Prothrombin Complex Concentrate for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Japanese SubjectsCSL Behring · completed · Acute Major Bleeding, Reversal of Coagulopathy · study director
- Ph3NCT02214225 · A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.Seqirus · completed · Influenza, Human · study director
- Ph4NCT02212106 · A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 YearsSeqirus · completed · Influenza, Human · study director
- Ph3NCT02172950 · An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia ACSL Behring · completed · Hemophilia A, Severe Hemophilia A · study director
- Ph3NCT02093897 · Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia ACSL Behring · completed · Congenital Hemophilia A · study director
- Ph3NCT02053792 · A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia BCSL Behring · completed · Hemophilia B · study director
- Ph3NCT01964989 · Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.Seqirus · completed · Influenza Virus · study director
- Ph3NCT01912456 · A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary AngioedemaCSL Behring · completed · Hereditary Angioedema Types I and II · study director
- Ph1NCT01760343 · A Study to Evaluate the Safety and Pharmacokinetics of Two Formulations of C1-esterase InhibitorCSL Behring · completed · Hereditary Angioedema Types I and II · study director
- Ph3NCT01662531 · A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia BCSL Behring · completed · Hemophilia B · study director
- Ph1/Ph2NCT01576523 · A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous RouteCSL Behring · completed · Hereditary Angioedema Types I and II · study director
- Ph2/Ph3NCT01496274 · A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia BCSL Behring · completed · Hemophilia B · study director
- Ph2/Ph3NCT01486927 · An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia ACSL Behring · completed · Hemophilia A · study director
- Ph1NCT01347190 · Safety and Tolerability Study of Liquid Alpha1 Proteinase Inhibitor (API) in Subjects With Cystic FibrosisCSL Behring · completed · Cystic Fibrosis · study director
- Ph3NCT01229007 · Study of Biostate® in Children With Hemophilia ACSL Behring · completed · Hemophilia A · study director
- Ph3NCT01224808 · Extension Study of Biostate in Subjects With Von Willebrand DiseaseCSL Behring · completed · Von Willebrand Disease · study director
- Ph3NCT01213446 · Study of Biostate® in Children With Von Willebrand DiseaseCSL Behring · completed · Von Willebrand Disease · study director
- Ph3NCT01184846 · Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating PolyneuropathyCSL Behring · completed · Chronic Inflammatory Demyelinating Polyneuropathy · study director
- N/ANCT01108848 · Patient Registry Study of Berinert® in Normal Clinical PracticeCSL Behring · completed · Includes: Hereditary Angioedema · study director
- Ph3NCT00945906 · An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII DeficiencyCSL Behring · completed · Factor XIII Deficiency · study director
- Ph2/Ph3NCT00941616 · Study of a pd VWF/FVIII Concentrate, Biostate®, in Subjects With Von Willebrand DiseaseCSL Behring · completed · Von Willebrand Disease · study director
- Ph3NCT00916656 · Fibrinogen Concentrate (Human) - Efficacy and Safety StudyCSL Behring · withdrawn · Afibrinogenemia, Hypofibrinogenemia, Fibrinogen Deficiency · study director
- Ph3NCT00885742 · A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII DeficiencyCSL Behring · completed · Factor XIII Deficiency · study director
- Ph2NCT00883090 · A Study of the Use of Factor XIII Concentrate in Patients With Inherited FXIII DeficiencyCSL Behring · completed · Factor XIII Deficiency · study director
- Ph3NCT00803101 · An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N (Kcentra) Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical ProcedureCSL Behring · completed · Reversal of Coagulopathy · study director
- Ph3NCT00751621 · Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)CSL Behring · completed · Primary Immunodeficiency (PID) · study director
- Ph3NCT00719680 · Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)CSL Behring · completed · Primary Immune Deficiency · study director
- Ph3NCT00708435 · Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant TherapyCSL Behring · completed · Blood Coagulation Disorders, Acute Major Bleeding · study director
- Ph4NCT00670007 · Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency.CSL Behring · completed · Emphysema, Alpha 1-proteinase Inhibitor Deficiency · study director
- Ph2NCT00496262 · Human Fibrinogen - PharmacokineticsCSL Behring · completed · Fibrinogen Deficiency · study director
- Ph3NCT00292981 · C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)CSL Behring · completed · Hereditary Angioedema · study director
- Ph3NCT00168025 · Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)CSL Behring · completed · Agammaglobulinemia, IgG Deficiency, Common Variable Immunodeficiency · study director
- Ph2/Ph3NCT00168103 · Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) AttacksCSL Behring · completed · Hereditary Angioedema · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 04:59 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.